Ignite Proteomics offers the only commercially available and clinically validated assay that measures both the expression and activation levels of drug targets in breast tumors. This innovative ...

Credit: Thinkstock Investigators explored the potential of a noninvasive ctDNA assay as a predictive biomarker for advanced or metastatic urothelial cancer ... of total cell-free DNA (cfDNA ...

Detailed price information for Predictive Oncology Inc (POAI-Q) from The Globe and Mail including charting and trades.